Aurobindo Pharma achieves record revenue in Q3 FY25 despite profit decline
Aurobindo Pharma Limited has reported its highest-ever quarterly revenue for the third quarter of fiscal year 2025, underlining its strong position in the global pharmaceutical ... Read More
Granules India gains key FDA approval for Unit V facility, marking major compliance milestone
Hyderabad-based Granules India Limited has achieved a significant regulatory milestone, securing an Establishment Inspection Report (EIR) with a “No Action Indicated” (NAI) status from the ... Read More
Glenmark Life Sciences’ Q1FY25 results shock industry with 9.7% revenue surge
Glenmark Life Sciences Limited (BSE: 543322, NSE: GLS), a prominent player in the pharmaceutical industry, has announced impressive financial results for the quarter ended June ... Read More